We examined the effect of sulfonylureas on the level of fructose 2,
perfusion system. The F-2, 6-P2 level in muscle was increased by adding glibenclamide or tolbutamide in a dose-dependent manner.
The stimulatory potency of each drug on F-2, 6-P2 formation was parallel to its hypoglycemic potency.
Sulfonylurea stimulation of muscle F-2, 6-P2 formation is thought to be an important extrapancreatic action improving the deranged carbohydrate metabolism in diabetics.
It is well known that the hypoglycemic effect of sulfonylurea is attributed in part to its extrapancreatic action. The effect of sulfonylurea on carbohydrate metabolism in the liver and peripheral tissues is the most important one among various extrapancreatic actions of the drug.
Sulfonylureas have been reported to stimulate glycogenesis and inhibit gluconeogenesis in the liver by itself or by enhancing insulin action (Fleig et al., 1984; Rinninger et al., 1984; Monge et al., 1986) . In addition, the drug potentiates insulin-induced recruitment of glucose transport carrier in adipocytes (Jacobs and Jung, 1985) and enhances insulin action on glucose uptake in skeletal muscle (Feldman and Lebovitz, 1969; Daniels and Lewis, 1982) .
Recently, we have reported that sulfonylurea stimulated liver fructose 2, 6-bisphosphate (F-2, 6-P2) formation and the stimulatory effect of the drug is in proportion to its hypoglycemic potency (Matsutani et al., 1984; Hatao et al., 1985) . F-2, 6-P2 was found to be a potential activator of phosphofructokinase, a key enzyme of glycolysis (Pilkis et al., 1981) , and the level of F-2, 6-P2 is known to be regulated by pancreatic hormones, glucagon and insulin (Richards and Uyeda, 1980; Richards and Uyeda, 1982) . Glucagon suppression of liver F-2, 6-P2 formation is released by tolbutamide (Matsutani et al., 1984) . These effects of the drug on the F-2, 6-P2 level have not been demonstrated in peripheral tissues.
In the present study, we investigated the effect of sulfonylureas on the level of muscle F-2, 6-P2 in a mouse hindlimb perfusion system.
Materials and Methods
Male ddy mice, weighing 25-30 gm, were at the concentration of 10-7 M stimulated F-2, 6-P2 formation significantly and the maximum effect of the drug was obtained at 10-6 M. But a higher concentration of the drug (10-5 M) did not exhibit any effect on the activator formation (Fig. 2) . The maximum effect of tolbutamide was observed at a concentration of 10-3M (Fig.  3) . There was no effect of tolbutamide at a higher concentratin (10-2M) as in the case of glibenclamide (data not shown 
reported that a decrease in F-2, 6-P2 associated with insulin deficiency was observed in the liver but not in skeletal muscle. However, the F-2, 6-P2 level in muscle reported by Dall'aglio et al.(1986) was much lower than that obtained in our study or in previous studies (Kuwajima and Uyeda, 1982; Thomas and Uyeda, 1986) . Our results clearly show that sulfonylurea raises the muscle F-2, 6-P2 level by twice the basal level or more. Daniels and Lewis (1982) reported that tolbutamide potentiated the glucose uptake in perfused rat hindlimbs, and our observations appear to support their results with respect to the mechanism of drug action. In addition, Uyeda et al. (1981) demonstrated that F-2, 6-P2 counteracts ATP or citrate inhibition of phosphofructokinase and decreases the Km value of the enzyme for fructose-6-phosphate in muscle.
These facts strongly suggest that the stimulatory effect of sulfonylurea on muscle F-2, 6-P2 formation plays an important role in improving the deranged carbohydrate metabolism in the muscle of diabetics by stimulating glycolysis.
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